2 edition of Targeting multicellular drug resistance mechanisms in ovarian cancer. found in the catalog.
Targeting multicellular drug resistance mechanisms in ovarian cancer.
Written in English
|The Physical Object|
|Number of Pages||191|
Overexpression of CDC25A has been reported in multiple cancers, such as ovarian cancer 18and hepatocellular carcino and correlated to a poor prognosis in patie The onco-promoting mechanism of CDC25A was considered to be a result of its regulatory role in cell cycle transit Author: Yiting Sun, Song Li, Lu Yang, Di Zhang, Zeyi Zhao, Jing Gao, Lian Liu. Epithelial ovarian cancer (EOC) is the most difficult cancer to cure in gynecological malignancy. Over 70 % of patients respond to chemotherapy initially, but the majority will relapse. Despite the emergence of a variety of cytotoxic anti-cancer agents and targeted therapy such as bevacizumab, control over the progression of EOC remains by: 6.
Purpose: Peritoneal metastasis is the most common pathway for the spread of ovarian cancer. Ovarian cancer cells in ascites prefer to aggregate into the more chemoresistant multicellular spheroids (MCSs), leading to treatment failure and disease recurrence. We previously established a suspension MCS model of ovarian cancer cells in vitro and found that the MCS cells acquired drug resistance Cited by: 3. that multicellular ovarian cancer spheroids develop intrinsic multidrug resistance with the appearance of quiescent cell areas. p27 protein is a determinant of such resistance and that down-regulation of p27 sensitizes the cells to Taxol. Furthermore, p27 up-regulates the P-gp protein expression in multicellular ovarian cancer spheroids cells (13).
Keywords:paclitaxel, drug resistance, reversal of drug resistance, in vivo drug resistance assays, mdr, pgp, tubulin, cytokine Abstract: It has been approximately ten years since the Food and Drug Administration (FDA) approved paclitaxel for the treatment of platinum resistant epithelial ovarian . "Indeed, by identifying new mechanisms underlying drug resistance in ovarian cancer, our study may allow future development of innovative approaches to .
Whats in a name: some consequences of the 1969 Children & Young Persons Act
Current foreign and Commonwealth periodicals in the Bodleian Library and in other Oxford libraries.
Remarks upon a pamphlet, intitled, Some doctrines in the superlapsarian scheme impartially examind by the word of God
Proceedings of the Symposium on Effective Use of Digital Computers in Structural Design.
Elements of educational psychology.
Lord of the Temple
Treaties and agreements of the Five Civilized Tribes
Insect Travellers (Technical bulletin / Pest Infestation Control Laboratory)
lignite field of northwestern South Dakota.
Thirteenth Hussars in the Great War
Final report of the Commission to Study Domestic Violence, December 2001.
Applied science and technological progress
A sales managers field letters to his men
All about the Merry tales of Gotham
story of the Constitution
In this review, the major and recently identified molecular mechanisms of drug resistance in ovarian cancer from relevant literature have been investigated. In the final section of the paper, new approaches for studying detailed mechanisms of chemo‐resistance have been briefly by: Abstract.
Alkylating agents, natural products and platinum complexes are the primary chemotherapeutic agents used in the treatment of patients with ovarian cancer.
Resistance frequently develops to all three classes of drugs and can be functionally separated into distinct biochemical pathways: (1) relative dose intensity plays a role in resistance to platinum complexes and to a lesser degree with alkylating agents; (2) induction of the membrane P‐ glycoprotein confers resistance Cited by: In this review, the major and recently identified molecular mechanisms of drug resistance in ovarian cancer from relevant literature have been investigated.
In the final section of the paper, new approaches for studying detailed mechanisms of chemo‐resistance Cited by: Molecular mechanisms of drug resistance in ovarian cancer. Norouzi-Barough L(1), Sarookhani MR(2), Sharifi M(3), Moghbelinejad S(4), JangjooS(5), Salehi R(3).
Author information: (1)Department of Molecular Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. (2)Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, by: of ovarian cancer relapse.
Advancement of novel therapeutics targeting DNA damage, cell metabolism, and endoplasmic reticulum present some of the novel strategies in the pipeline. Emerging compelling pre-clinical data with novel antibody-drug conjugates targeting various surface receptors in ovarian cancerAuthor: Dmitriy Zamarin.
Ovarian cancer is responsible for 4% of deaths from cancer in women. Treatment comprises a combination of surgery and chemotherapy, but Cited by: 7 MULTIPLE DRUG RESISTANCE. Research is in progress for understanding the mechanism of drug resistance in OC. Some of these mechanisms include increased DNA repair, overexpression of surface p ‐glycoprotein, increased cellular levels of glutathione (GSH) and glutathione S‐transferases causing de‐toxification of platinum agents and taxol.
52 Cancer cells develop certain transport Cited by: 4. Spheroids can be generated by culturing adherent ovarian cancer cells under conditions where attachment to matrices is prevented.
This type of cellular manipulation has been used in the past primarily to investigate the mechanism(s) of drug resistance in three-dimensional solid tumors.Cited by: Tumor cells coopt to multicellular aggregation for their survival and, thereby, develop resistance to the killing effects of chemotherapeutics.
12, 39, 55, 56 By forming multicellular aggregates Cited by: 6. While efflux via ABC transporters is a normal physiological process, it is also a known mechanism of drug resistance in cancer cells.
Three transporters—multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein (BCRP)—are implicated in many drug resistant by: Emerging drugs aim at targeting the genomic integrity and replication machinery in ovarian cancer.
While the antiproliferative activity of Xanthium strumarium L. extract (XFC), a traditional herbal medicine, is believed to alter the mitotic apparatus of Chinese hamster ovary epithelial cells, its capacity to target and overcome the chemoresistance phenotype in ovarian cancer is : Marbelis Francisco Fernandez, Cyndia Charfi, Janet Piloto-Ferrer, Maria Lidia González, Sylvie Lamy.
Novel treatments targeting specific molecular factors of heterogeneity have been used to reverse drug resistance in ovarian cancer.
In a phase I clinical trial of the platinum and taxane resistant or refractory high-grade epithelial ovarian cancer patients, AKT inhibitor perifosine plus docetaxel appears to be effective in patients with the Cited by: Cancer drug resistance continues to be a major impediment in medical oncology.
Clinically, resistance can arise prior to or as a result of cancer therapy. In this review, we discuss different mechanisms adapted by cancerous cells to resist treatment, including alteration in drug transport and metabolism, mutation and amplification of drug targets, as well as genetic rewiring which can lead to Cited by: 8.
Targeting DNA Damage Response and Repair as A Therapeutic Strategy for Ovarian Cancer 9. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer Antibody Drug Conjugates in The Treatment of Epithelial Ovarian Cancer Abstract.
The development of multidrug resistance (MDR) to chemotherapy remains a major challenge in the treatment of cancer. Resistance exists against every effective anticancer drug and can develop by numerous mechanisms including decreased drug uptake, increased drug efflux, activation of detoxifying systems, activation of DNA repair mechanisms, evasion of drug-induced Cited by: Ovarian cancer cells evade the immune system as well as chemotherapeutic and/or biologic treatments through inherent or acquired mechanisms of survival and drug resistance.
Depending on the cell type and the stimuli, this threshold can range from external forces such as blunt trauma to programmed processes such as apoptosis, autophagy, or : Linah F.
Al-Alem, Andrew T. Baker, Unnati M. Pandya, Eric L. Eisenhauer, Bo R. Rueda. Peritoneal metastasis is the most common pathway for the spread of ovarian cancer. Ovarian cancer cells in ascites prefer to aggregate into the more chemoresistant multicellular spheroids (MCSs), leading to treatment failure and disease recurrence.
We previously established a suspension MCS model of ovarian cancer cells in vitro and found that the MCS cells acquired drug resistance to Cited by: 3.
Niraparib might be used to treat advanced ovarian cancer after several chemotherapy drugs have been tried and if the cancer started growing 6 months or more after the last chemo was given These drugs have been shown to help shrink or slow the growth of some advanced ovarian cancers for a time.
Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance introduces the basic concepts and advanced understanding of cancer stem cells, covering general overviews, organ-specific identifications, and their characteristic mechanisms. The book also explores innovative therapeutic strategies in preclinical and clinical trials to target cancer stem.
The development of resistance to cancer therapy is a major predictor of patient mortality. Therefore, understanding resistance mechanisms is key to improving therapeutic by: 3.
The Wistar Institute. (, October 9). Mechanism of resistance to novel targeted therapy for ovarian cancer identified.
ScienceDaily. Retrieved Febru from Novel cause of ovarian cancer drug resistance identified Dana-Farber Cancer Institute scientists have shed new light on why some ovarian cancers don’t respond to or learn to evade standard chemotherapy and targeted drugs.
They say the discovery could aid in developing strategies to combat ovarian drug resistance.The term ‘drug resistance’ is used to illustrate the decreased effectiveness of a drug in curing a disease or alleviating the symptoms of the patient.
This phenomenon helps tumors to survive the damage caused by a specific drug or group of drugs. In this context, studying the mechanisms of drug resistance and applying this information to Cited by: 4.